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Abstract 
Introduction: Currently there are several advanced guiding techniques for pathoanatomical di-
agnosis of incidental solitary pulmonary nodules (iSPN): Electromagnetic navigation (EMN) with or 
without endobronchial ultrasound (EBUS) with miniprobe, transthoracic ultrasound (TTUS) for 
needle approach to the pleural wall and adjacent lung and computed tomography (CT) -guidance 
for (seldom if ever used) endobronchial or (common) transthoracical approach. In several situa-
tions one technique is not enough for efficient diagnosis, therefore we investigated a new diag-
nostic technique of endobronchial guided biopsies by a Cone Beam Computertomography 
(CBCT) called DynaCT (SIEMENS AG Forchheim, Germany). Method and Material: In our study 
33 incidental solitary pulmonary nodules (iSPNs) (28 malignant, 5 benign; mean diameter 25 
+/-12mm, shortest distance to pleura 25+/-18mm) were eligible according to in- and exclusion 
criteria. Realtime and onsite navigation were performed according to our standard protocol.22 All 
iSPN were controlled with a second technique when necessary and clinical feasible in case of 
unspecific or unexpected histological result. In all cases common guidelines of treatment of dif-
ferent iSPNs were followed in a routine manner. Results: Overall navigational yield (ny) was 91% 
and diagnostic yield (dy) 70%, dy for all accomplished malignant cases (n=28) was 82%. In the 
subgroup analysis of the invisible iSPN (n=12, 11 malignant, 1 benign; mean diameter 15+/-3mm) 
we found an overall dy of 75%. For the first time we describe a significant difference in specifity of 
biopsy results in regards to the position of the forceps in the 3-dimensional volume (3DV) of the 
iSPN in the whole sample group. Comparing the specifity of biopsies of a 3D-uncentered but inside 
the outer one third of an iSPN-3DV with the specifity of biopsies of centered forceps position 
(meaning the inner two third of an iSPN-3DV) reveals a significant (p=0,0375 McNemar) difference 
for the size group (>1cm) of 0,9 for centered biopsies vs. 0,3 for uncentered biopsies. Therefore 
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only 3D-centered biopsies should be relied on especially in case of a benign result. Conclusion:The 
diagnostic yield of DynaCT navigation guided transbronchial biopsies (TBB) only with forceps is at 
least up to twofold higher than conventional TBB for iSPNs <2cm. The diagnostic yield of DynaCT 
navigation guided forceps TBB in invisible SPNs is at least in the range of other navigation studies 
which were performed partly with multiple navigation tools and multiple instruments. For future 
diagnostic and therapeutic approaches it is so far the only onsite and realtime extrathoracic 
navigation approach (except for computed tomography (CT)-fluoroscopy) in the bronchoscopy 
suite which keeps the working channel open. The system purchase represents an important in-
vestment for hospitals but it is a multidisciplinary and multinavigational tool with possible access via 
bronchial airways, transthoracical or vascular approach at the same time and on the same table 
without the need for an expensive disposable instrument use. 
Key words: solitary pulmonary nodule, cone-beam computed tomography (CBCT), electromag-
netic navigation bronchoscopy (EMN, ENB), transbronchial biopsy (TBB). 
Introduction 
Incidence of lung cancer is currently 
1/1850-1/2000 per inhabitant in the United States 
which means >200000 newly diagnosed cases and  
>160000 deaths per year.1 The population is aging 
with more chronic obstructive pulmonary disease 
patients having one of the most important risk factors 
for lung cancer.2 The prevalence of iSPNs in an unbi-
ased population on thoracic imaging with X-ray 
photography (XR) is described with 0.2% 3 and with 
CT 0.5%4 . In comparison to a population at risk the 
values are different for XR 7%  and CT 23%, which of 
these are malignant in the XR group with  0.4% and in 
the CT group with 2.7%. From a clinical perspective 
this means fifty times more iSPNs in patients at risk 
(in comparison to a population without risk) but only 
every tenth is malignant. Following actual guidelines 
for the management of iSPN this would dramatically 
increase the rate of futile thoracotomy especially in a 
group with patients at risk e.g. poor lung function if 
no other pre-operative diagnostic approach (prefera-
bly with navigation support) is accomplished.5 Fur-
thermore, the relative risk of an iSPN in an unbiased 
population on CT to develop lung cancer according to 
size is6:  <4mm 1%; >8mm 10-20%; <1cm: 15%7,8; 
>20mm: 50%; >3cm: >95%7,8. Moreover volume dou-
bling time (VDT) is not differentiating well between 
malignant and benign9: Small cell lung cancer (SCLC) 
shows a typical VDT of 30 days which means from a 
clinical perspective an easy cut-off value. On the other 
hand small well differentiated adenocarcinomas of 
the lung (AC) appear with a VDT of 500-750 days 
which is a difficult-to-handle cut-off. From a clinical 
perspective VDT has no major value. It was also ob-
served in the national lung screening trial (NCI U.S.)9 
that using low dose CT (<1,5 mSv) in a patient popu-
lation at risk (smoking history) reduces mortality due 
to lung cancer around 20%. The relative risk of an 
iSPN in an unbiased population on positron emission 
tomography (PET)-CT to become lung cancer ac-
cording to SUV>2.5 is 90%.10 Additionally, we have a 
reduction of “futile thoracotomies” for iSPN with the 
addition of PET-CT after conventional staging in 
non-small cell lung cancer (NSCLC) 11 from 42% 
without PET-CT to 21% with PET-CT (but with no 
improvement of overall survival). Based on this in-
formation neither CT nor PET-CT is the definite solu-
tion for the individual question of dignity of an iSPN, 
once again it remains the hand of the interventional 
doctor to clarify the situation with the leading words 
of “tissue is the issue”. Based on the American College 
of Chest Physicians (ACCP 2007) guidelines on TBB12 
the expected sensitivity for all malignant iSPN < 3cm 
is 33 to 50%. From a clinical perspective this guideline 
is not covering the aspect of “correct negative results”: 
At the end of a diagnostic process one wants to know 
if a benign histological result indicates a pathoana-
tomically benign iSPN. This is not the value of sensi-
tivity but of specifity of a navigated biopsy indicating 
if a benign (possibly correct negative) `navigated` 
histology represents a truly benign iSPN. Electro-
magnetic navigation and fluoroscopy together show a 
dy in the range of 63-74% for iSPN with a mean di-
ameter of at least 2,4cm+/-1,5cm or bigger.12 In iSPN 
< 2cm the application of miniprobe EBUS +/- fluor-
oscopy in addition to multiple instruments (sheath, 
curette, brush and forceps) the dy was reported to be 
between 44,4% up to 72.8%. The combination of elec-
tromagnetic navigation and miniprobe EBUS  +/- 
multiple instruments raised the number of dy even for 
iSPN <2cm over 80%.12 However the cost per exami-
nation in comparison to conventional TBB is at least 
1000 € and therefore very expensive. Reimbursement 
of this technique is not available in many health sys-
tems. There are some aspects to remember: a) These 
navigation tools are used endobronchially and there-
fore block the working channel. Only Veran Systems 
has invented electromagnetic fitted forceps and other 
tools so far.  Except for this system it is of notice that 
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neither the performance of the all-decisive biopsy nor 
any endobronchial therapy (in future) can be moni-
tored by these devices. B) The iSPNs in upper lobes 
are easier to manage than in lower lobes - this counts 
as well for all sophisticated devices. One has to re-
member that due to the elastic recoil all navigation 
systems working as 2-step-system the dataset for vir-
tual bronchoscopy is accomplished in an awake pa-
tient taking a deep breath while the examination with 
this 3D-dataset takes place later in a patient asleep 
with a total different diaphragm position. This factor 
influences especially the navigation results in the 
lower lobes. C) Despite the application of  sophisti-
cated devices the dy in large (>3cm) iSPNs is inter-
estingly enough not higher - maybe worse than in 
smaller iSPNs.12 D) It has to be accepted that in gen-
eral there is an obvious difference between naviga-
tional and diagnostic yield of in average of 20%.13 
Therefore one should try to identify what influences a 
successful navigation with high specifity and high 
sensitivity for malignancy besides size and lobar lo-
cation for iSPNs. The following items should be con-
sidered: 
A) The growing pattern of a “homogenous radi-
ological” iSPN is spoken from a pathoanatomical 
point of view in reality inhomogenous: All bronchol-
ogists experience often the finding of  benign histol-
ogy like organizing pneumonia / anthracosis or scar 
at the rim of the radiological appearance of a malig-
nant iSPN. Therefore in case of benign histology one 
has to ask if we can believe in his own results. 
B) The detectability of distal airways is even in 
CT limited to a diameter of no less than 1,5mm which 
is around the 8th segmentation of the bronchial tree. 
C) The site of the iSPN in relation to anatomical 
pathway influences the yield of a navigated endo-
bronchially approach: If forceps/brush is used an 
anatomical pathway ( e.g. a bronchus sign) into the 
lesion is needed. If needle is used an extraanatomical 
pathway is possible. Notable is the fact that less 
steerability of a peripheral needle position only allows 
to advance an iSPN over 1-2cm and needs greater 
experience than a conventional TBB.   
D) Distortion of airway anatomy allows elec-
tromagnetic navigation systems the statement of 
‘’successful navigational yield’’ although the diag-
nostic yield is zero. This is due to the fact that the op-
erator can distort by manual power via the broncho-
scope the actual airway anatomy so that a bronchial 
airway containing the EMN-sensor only ‘’kisses’’ the 
correct position without anatomical opening towards 
the target of the neighboured area. 
E) Electromagnetic navigation systems always 
depend on at least one pre-endoscopy CT which is 
obligatory for the realisation of a virtual bronchosco-
py dataset for the second step: The examination itself.  
In other words: All electromagnetic systems so far 
work as a 2-step-system, the 3-dimensional navigation 
dataset is not composed during the definite examina-
tion. Therefore these systems may give a realtime 
feedback of the navigation process but the anatomical 
3D-datset is not composed onsite – there is always a 
time- and performance-gap between anatomical real-
ity and virtual navigation anatomy. 
In regards to the growing pattern of an iSPN 
positioning could be measured in comparison to the 
projection of the forceps and its position to the out-
lined iSPN-3DV projection. In this study we always 
aimed to reach the inner 2/3 of an iSPN-3DV (Figure 
1): This is our definition of a centered biopsy. In con-
trast the outer 1/3 of an iSPN-3DV is still inside but 
uncentered and therefore of expected different value.  
Both situations – centered and inside – have the qual-
ity of a positive navigational yield.  This concept is 
based on the fact that a bronchus sign leading some-
where into an iSPN-3DV is one of the strongest pre-
dictors of a correct diagnostic yield.14 
 
Figure 1: In big SPN: Accuracy in regards to diagnosis is a question of detection AND positionning  intratumoral.  In regards to navigation accuracy 
is defined  by detection only. (intratumoral = inside/borderline or centered) In small SPN <15mm (per definition): Accuracy in regards to diagnosis and 
navigation is a question of (more or less) detection only (hit or fail). 
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In regards to the detectability of small bronchial 
airways our standard examination protocol uses in-
termediate high airway pressure15: It is expectable 
that the timely limited hyperinflation will deliver 
more CT-contrast (air in contrast to bronchial wall, 
parenchyma and consolidation) and dilate smaller 
bronchioli meaning a deeper segmentation than nor-
mal, at least in some DynaCT-datasets if any patient 
or organ movement could be avoided by the proto-
col.15 Therefore we expect partly a higher resolution 
with our DynaCT protocol than on conventional 
HRCT and therefore in principal better results. 
In regards to EMN devices we already described 
that DynaCT guided endobronchial navigation as 
one-step realtime and onsite navigation has clear ad-
vantages over all 2-step-navigation methods.15 In our 
current study we will elicit the place of DynaCT in 
interventional chest medicine. 
Patients and Methods 
General considerations on Cone-Beam 
Computed Tomography (CBCT) 
Digital flat-panel detector CBCT has been 
adapted for the use with C-arm systems. This config-
uration allows the standard 2D projection functional-
ity like fluoroscopy as well as volumetric computed 
tomography (CT) capabilities within the interven-
tional suite. Currently this technology is used for 
many fields of interventional radiology procedures 
like cerebral aneurysm characterization and in-
tra-arterial liver tumor embolization. The central dif-
ference between conventional multidetector CT and 
CBCT is that CBCT acquires information using a 
high-resolution two-dimensional detector instead of 
detector slices used for Multi Slice CT (MSCT). For 
acquiring the 3D dataset the C-arm needs to rotate by 
200° (180° plus fan angle) around the target that re-
mains stationary during acquisition.16  For our image 
acquisition we used the 5 seconds run with 248 single 
2D- projections. This protocol (without contrast agent 
except for air) is providing sufficient image quality for 
clearly displaying the bronchial structures as well as 
the target itself. These data are sent automatically to a 
workstation where the reconstruction is finished 
within less than 15 seconds (s). At the workstation the 
target itself as well as the path within the bronchial 
tree are identified and marked with manual annota-
tion tools (Siemens iguide toolbox). In the following 
step these markers are projected and overlaid to the 
fluoroscopic image.  This technique allows the physi-
cian to match his instruments (bronchoscope, forceps) 
to the overlay and in consequence navigate correctly 
to the (fluoroscopy-invisible) target. The major limi-
tation of this technique is a significant lower image 
quality if there is target movement during 3D acqui-
sition. For eliminating this factor the absence of 
spontaneous respiration is mandatory – the patient is 
put into apnea. The connected ventilation system is 
maintaining the inspiration phase during acquisition 
as well as the navigation process. This leads to an 
accurate match between the 3D dataset and the 
fluoroscopic image. For visualization of lung struc-
tures there is no need for artificial contrast medium 
except for air which makes 800-1000 HU contrast dif-
ference in comparison to bronchial wall. The issue of 
getting the contrast medium AIR into small subpleu-
ral bronchioli can be resolved with the following 
rules. (Figure 4.). The diaphragm should be kept still, 
no movement should be performed especially during 
data acquisition. The small subpleural bronchioli and 
especially the >8th generation should be dilated for 
CT-contrast enhancement. This action can be per-
formed with supranormal constant airway pressure. 
Moreover the patient should be kept in the same po-
sition for data acquisition and examination. Complete 
and constant apnea by distinct sedation protocol 
during acquisition have been applied up to 90 
minutes without any adverse effects.15 Complete ap-
nea and constant inspiratory positioning of the dia-
phragm should be acquired between acquisition and 
navigation to realize best biopsy results.17 (Figure 5.). 
Furthermore a distinct  jet-ventilation protocol should 
be applied with nasal-jet-catheter to keep optimal 
ventilation setting and periods of complete apnea 
altering with sufficient ventilation for biopsy under 
expiration (in order to reduce the risk of pneumotho-
rax).15 (Figure 6,7,8.).  
Study design  
Prospective real world, all comers study design 
including forty-nine patients with 50 iSPNs. There 
was no limit in regards to age (24-89 years), body 
mass index (mean 31kg/m2 height, maximum 
40kg/m2 height) or clinical condition of any comor-
bidities ( any stage of COPD, heart insufficiency, etc.). 
Purpose 
The purpose of our study was to investigate the 
accuracy of DynaCT navigation as an onsite and ex-
trathoracical navigation tool in our bronchoscopy 
suite especially in comparison to standard trans-
bronchial biopsy (TBB) under fluoroscopy. Therefore 
we did not use any other instrument for obtaining 
tissue than forceps for TBB. A special focus was put 
on the so called “invisible” iSPN on fluoroscopy (e.g. 
<2cm depending on the location in the lung) and the 
information given by the iSPN-3DV-dataset. The vis-
ibility was announced by one blinded nurse before 
DynaCT under fluoroscopy in the DynaCT suite. By 
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choice of the physician it was allowed to use periph-
eral navigation devices like Superdimension`s steer-
ing catheter (without the electromagnetic device) or 
curette of Olympus.  
Inclusion and Exclusion Criteria 
1. The patients were included only after in-
formed consent (especially over additional radiation 
exposure by DynaCT application and intermediate 
high pressure sustained jet-ventilation). All patients 
were presented with at least one iSPN on initial (ex-
ternal) XR or thoracic CT (TCT) scan. All patients 
were part of the daily routine program in our hospital. 
2. Before enrollment all patients had to prove 
favorable conditions for endoscopic biopsies under 
jet-catheter-ventilation in the DynaCT suite and no 
major ear, nose and throat (ENT) problems. At all 
patients without an initial TCT but with suspicious 
iSPN on XR we performed after enrollment an addi-
tional diagnostic standard TCT. Before DynaCT nav-
igation all enrolled patients had an additional trans-
thoracic ultrasound to exclude pleural effusion in the 
DynaCT suite due to the fact that compression of dis-
tal airways (DA) by pleural effusion would influence 
negatively the visualization of DA hyperinflation and 
increase the risk of pneumothorax by reduced com-
pliance. 
3. In standard TCT projections the largest diam-
eter were measured for height, width and depth (h,w 
and d). All diameters had to be ≥ 10mm at least in the 
lung window on initial TCT. 
4. If an alternative way of diagnosing iSPN than 
TBB were feasible (e.g. transthoracic puncture in case 
of a pleural carcinosis/exudates, ultrasound –guided 
transthoracic needle approach in case of subpleural 
consolidation, central biopsy in case of endoscopic 
central process) the patient would automatically be 
excluded from the DynaCT navigation analysis. 
5. The inability to visualize a peripheral bron-
chial airway towards the iSPN (e.g. extreme distor-
tion) after the segmental ostia until 1 cm towards the 
target lead to exclusion from the DynaCT navigation 
analysis. 
6. Pleural effusion lead to exclusion of the anal-
ysis as well as diaphragmatic paresis. 
7. iSPN highly suspicious for hemartoma were 
not enrolled for biopsy and only followed for 9 
months. This is due to the fact that the establishment 
of a diagnosis of a hemartoma is rarely successful 
with a histology given by forceps. 
8. Any other iSPN was controlled by a second 
method like surgery, transthoracic approach, and if 
feasible only follow-up (3,6 and 9 months) in case of 
benign histology. 
Patients 
In total forty-nine patients were enrolled with 
fifty iSPNs, exclusion of seventeen iSPN were docu-
mented, therefore thirty-three iSPNs to be analyzed 
for DynaCT guided endobronchial navigation forceps 
biopsy. In detail we have found on the 17 initially 
excluded iSPNs the following additional findings: 
a) Pleural carcinosis (one case) and contact to 
parietal pleura (7cases: 3 benign, 4 malignant). 
b) One iSPN < 10mm in at least one diameter: In 
follow-up over 9 months this case was diagnosed as a 
benign nodule. 
c) Due to diaphragmatic paresis we excluded one 
iSPN of less than 2cm of the analysis which turned out 
to be malignant. 
d) 2 initially enrolled iSPNs on XR fulfilled the 
criteria of a hemartoma on TCT and were followed up 
for 9 months without any change in appearance. 
e) We have found 3 incidental central carcino-
mas. 
f) One case appeared with an iSPN of 15mm only 
at interlobar site belonging more to the pleural surface 
without bronchial access. This nodule was diagnosed 
as adenocarcinoma of the lung by surgery. 
g) There were 2 missed follow-ups due to early 
unexpected cardiovascular death and denial of sur-
gery including disappearance of the patient. Both 
cases presented with a negative navigational yield. 
Both cases are believed to be malignant. 
All these diagnosis were made upon conven-
tional techniques without the use of a CBCT. 
Feasibility 
In total no life threatening major adverse effects 
were observed despite intermediate apnea and hy-
perinflation for navigation. There were two pneumo-
thoraces treated by drainage in the next day (2/33 
means ≤ 6%). One non-life threatening bradycardia 
and hypotension occurred due to aggressive sedation 
(midazolam, propofol and remifentanyl) which was 
treated with saline, atropine and akrinor. Dry mucosa 
was regularly observed due to jet-ventilation without 
humidification. The heavier the patients the more 
prolonged hyperinflation pressure by jet-catheter 
ventilation was needed (working pressure up to 3.5 
bar for 20 seconds controlled and uptitrated stepwise 
under fluoroscopy looking at the deepest position of 
the diaphragm). Moreover, all examinations were 
performed in flexible technique with nasal 
jet-catheter. A rigid bronchoscopy was available but it 
was reducing the 3D-dataset quality by metal arti-
facts. With the hereby used protocol there was no 
essential need for anaesthesiologists .15 
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General consideration 
Navigation is positive if 
In posterior-anterior (pa) standard projection the 
targeted volume can be reached inside the borders by 
the forceps and the 3-edges-angulation is positive 
keeping the forceps “inside the projection of the tar-
geted volume”. Inside the borders means as forceps 
positioning: Position of the forceps is in the outer 1/3 
of an iSPN-3DV. Centered means: Position of the for-
ceps is in the inner 2/3 of an iSPN-3DV. 
3-edges-angulation 
The degree needed for angulation to accurate 
spatial accordance between anatomy and navigation 
is dependent upon the nodule size and position of the 
forceps/instrument. In general an angulation of 20-30 
degrees at least is needed according to other DynaCT 
applications.  A positive 3-edge-angulations means a 
successful navigation and consists of a positive 
pa-projection and 3 different angulations in different 
directions ‘’over the edges’’. The technique of 
3-edge-angulation is described elsewhere.15 
Results 
Out of thirty-three iSPNs twenty-eight iSPNs 
were diagnosed to be malignant and five were benign. 
In specific we missed one benign and two malignant 
iSPNs due to negative navigation. In 2 patients fol-
low-up method was not possible due to denial of 
surgery and death. The overall ny was  91% in the 
whole group. The overall dy was 70%. The dy for all 
possible malignant iSPNs was 82%. If we include the 
two patients assuming malignancies which were ex-
cluded for missed follow-ups  (due to death/denial 
for surgery) the dy for malignancy was 77% in the 
whole sample. (Figure 2.)  For all iSPN > 1cm the 
McNemar-Test (p=0.0375) for specifity inside vs. 
centered biopsies showed a significant result with 
high differences: The specifity of centered biopsies 
was 0,67-1,0 overall subgroups according to size, for 
inside biopsies 0,29-0,33. (Figure 3.) 
Looking at the size subgroups (<2cm and  >2cm) 
overall diagnostic yield was 75% (15+3mm) and 67% 
(30+11mm) respectively. In both subgroups the 
sensitivity for malignancy was 82%. 
 
 
Figure 2. Statistics along with navigation. 
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Figure 3. Statistical analysis. 
 
Figure 4. Where is the place for DynaCT in Interventional Chest Medicine ? 
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Figure 5. CT-dataset in XR: 3-dimensional volume information projected into c-arm fluoroscopy. 
 
 
Figure 6. Applying 3-dimensional DynaCT dataset: ‘Dotting‘ a pathway in virtual endoscopy or standard CT-projections towards the target up to the 12th 
segmentation. 
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Figure 7. Advancing an iSPN by a navigation device along the 3D-overlay: Distortion of the airway due to navigation force. 
 
Figure 8. Applying 3-dimensional DynaCT-dataset: Outlining the target in 3 standard axis. 
 
Discussion 
Comparing DynaCT with fluoroscopy guided 
TBB of iSPNs the following results where found: Sen-
sitivity for malignancy in this study for iSPN ≤ 2cm 
(15mm ± 3mm) was 82% which is much better than 
the described sensitivity for fluoroscopy guided con-
ventional TBBs in iSPNs of the same size with a mean 
value of 33%. 17-19 The same counts for the described 
sensitivity of malignant iSPNs > 2cm with a mean 
value of 62% in comparison to again 82% in this 
study.17-19 Comparing DynaCT guided TBBs in re-
gards to invisibility of iSPNs (that is to say the sub-
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group of <2cm with a mean diameter of 15±-3mm) we 
found a sensitivity for malignancy of 82% and for the 
size subgroup of <3cm (with a mean diameter 
19+/-5mm meaning nearly invisibility) a sensitivity of 
76%. This is comparable to published literature from 
Eberhardt and colleagues showing a sensitivity of 
70,3% for invisible iSPNs diagnosed with the help of 
minprobe EBUS under fluoroscopy.14 In the case 
where the iSPN cannot be reached intrabronchially, 
the iguide needle guidance for transthoracic approach 
should be used.20,21 Comparable accuracy between the 
DynaCT guided transthoracic approach21 (93%) and 
the DynaCT guided endobronchial approach in cen-
tered biopsies (94%) has been observed in our study. 
Of notice is the fact that in our study only in 6% a 
pneumothorax occured vs. 14% resp. 26% in the radi-
ological study.21 Of interest is the analysis about 
specifity of a biopsy result in regards to the position of 
the forceps in the iSPN: Our results indicate that one 
only can trust a benign biopsy histology if it is taken 
of the central part (inner 2/3 of a 3DV) of the nodule. 
Although this is a routine and major clinical question 
it is not addressed to the best of our knowledge in 
other studies or guidelines in the area of interven-
tional pulmonology before.  And there is no other 
navigation instrument than CBCT (except for 
CT-fluoroscopy) which can ‘foresee’ the value of a 
possible biopsy along the 3D-dataset. All 
EMN-systems are using an artificial ‘rounded’ or 
‘smoothed’ 3DV of the targeted iSPN. Our results here 
refer back to the ‘exactly outlined’ 3DV of an iSPN. In 
that context CBCT technology is unique. 
Finally this study shows that a new method for 
endobronchial navigation has its limit: 
A) Nearly one third of all initially enrolled iSPNs 
were excluded from analysis due to protocol which 
means a certain bias. These cases were diagnosed 
along the routine program of our clinic. Although the 
remaining number to be analyzed is small it is quite 
comparable with other studies.12 
B) On first sight the additional radiation expo-
sure of less than 2mSv15 is a disadvantage. Of notice is 
the fact that for electromagnetic navigation sytems a 
complete additional multi-slice TCT with an average 
value of around 7 mSv is necessary15, in some systems 
(like Veran Systems) even 2 (in inspiration and 
exspiration) TCTs are required before application of 
such a navigation system. Therefore as shown in an-
other publication the added radiation exposure by 
DynaCT navigation to a patient is in comparison to 
many other CT and navigation applications consid-
erably very low.15 C) As prolonged and controlled 
apnea in hyperinflation is crucious for the whole 
method one has to be accustomed to 
jet-catheter-ventilation and this herein applied pro-
tocol.15 D) Increased overweight or thoracical defor-
mation limits the jet-ventilation-effect and increases 
the risk of pneumothorax especially over convention-
al TBB. 
Conclusion 
DynaCT guided endobronchial navigation is to 
the best of our knowledge (except for CT-fluoroscopy) 
the only realtime and onsite extrathoracic navigation 
system. It is therefore assumable that in future thera-
peutic approaches in local lung diseases under navi-
gation guidance will take place in such a DynaCT 
suite as the working channel of a bronchoscope is not 
blocked by navigational instruments. So far there is no 
need for special and expensive one-way instruments. 
Furthermore it has the advantage if necessary to skip 
over to a navigated transthoracical approach on the 
same table during the same examination. Diagnostic 
yield of DynaCT guided forceps biopsies are basically 
twofold better than conventional guided biopsies 
under fluoroscopy especially in nodules less than 2 
cm. In under fluoroscopy invisible nodules the diag-
nostic yield of DynaCT guided TBBs are in the range 
of TBBs guided by other navigational tools like elec-
tromagnetic navigation systems and/or miniprobe 
EBUS. The purchase of such a system represents a 
major investment but it is at the same time a multi-
disciplinary tool which can be used by many other 
disciplines. 
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